Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network
Chan Yoon Cheah,Chan Yoon Cheah,Anupkumar George,Eva Giné,Annalisa Chiappella,Hanneke C. Kluin-Nelemans,Wojciech Jurczak,Katarzyna Krawczyk,Heidi Mocikova,Pavel Klener,David Šálek,Jan Walewski,Michal Szymczyk,Lukas Smolej,Rebecca Auer,David Ritchie,David Ritchie,Luca Arcaini,Michael E. Williams,Martin Dreyling,John F. Seymour,John F. Seymour +21 more
Reads0
Chats0
TLDR
In MCL, central nervous system involvement is uncommon, although some features may predict risk, and once manifest outlook is poor, some patients who receive intensive therapy survive longer than 12 months.About:
This article is published in Annals of Oncology.The article was published on 2013-08-01 and is currently open access. It has received 89 citations till now. The article focuses on the topics: Mantle cell lymphoma & International Prognostic Index.read more
Citations
More filters
Journal ArticleDOI
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
TL;DR: This work presents a meta-analysis of 120 cases of central giant cell granuloma in mice over a 12-month period and shows clear trends in survival and morbidity during the first year of treatment with chemotherapy.
Journal ArticleDOI
Mantle Cell Lymphoma
TL;DR: This work reviews recent advances in the understanding of MCL biology and outlines the recommended approach to therapy, including choice of chemoimmunotherapy, the role of stem-cell transplantation, and mechanism-based targeted therapies, on the basis of a synthesis of the data from published clinical trials.
Journal ArticleDOI
Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management.
Preetesh Jain,Michael Wang +1 more
TL;DR: The following aspects of MCL continue to pose a challenge: disease transformation, role of the cytokine‐microenvironmental milieu, incorporation of positron emission tomography‐computerized tomography imaging, minimal residual disease in the prognosis, circulating tumor DNA testing for clonal evolution, predicting resistance to BTK inhibitors, and optimal management of patients who progress on BTK/Bcl2 inhibitors.
Journal ArticleDOI
Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse.
Sophie Bernard,Lauriane Goldwirt,Sandy Amorim,Pauline Brice,Josette Brière,Eric de Kerviler,Samia Mourah,Samia Mourah,Hélène Sauvageon,Catherine Thieblemont +9 more
TL;DR: It is confirmed that ibrutinib crosses the blood-brain barrier with parallel pharmacokinetic analyses in plasma and cerebrospinal fluid using a validated LC-MS/MS method and responses were ongoing after 2 months to 1 year of follow-up.
Journal ArticleDOI
Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.
Yuqin Song,Keshu Zhou,Dehui Zou,Jianfeng Zhou,Jianda Hu,Haiyan Yang,Huilai Zhang,Jie Ji,Wei Xu,Jie Jin,Fangfang Lv,Ru Feng,Sujun Gao,Haiyi Guo,Lei Zhou,Rebecca Elstrom,Jane Huang,William Novotny,Rachel Wei,Jun Zhu +19 more
TL;DR: These results demonstrate high and durable ORR and CR rates in patients with relapsed/refractory MCL and Zanubrutinib was generally well tolerated; grade ≥3 BTK inhibitor-associated toxicities were uncommon.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Eva Hoster,Martin Dreyling,Wolfram Klapper,Christian Gisselbrecht,Achiel Van Hoof,Hanneke C. Kluin-Nelemans,Michael Pfreundschuh,Marcel Reiser,Bernd Metzner,H. Einsele,Norma Peter,Wolfram Jung,Bernhard Wörmann,Wolf-Dieter Ludwig,Ulrich Dührsen,Hartmut Eimermacher,Hannes Wandt,Joerg Hasford,Wolfgang Hiddemann,Michael Unterhalt +19 more
TL;DR: The MIPI as discussed by the authors is the first prognostic index particularly suited for mantle cell lymphoma patients and may serve as an important tool to facilitate risk-adapted treatment decisions in patients with advanced stage MCL.
Journal ArticleDOI
Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma
Lauren E. Abrey,Tracy T. Batchelor,A. J. M. Ferreri,Mary Gospodarowicz,Elisa Jacobsen Pulczynski,Emanuele Zucca,Justine R. Smith,Agnieszka Korfel,Carole Soussain,Lisa M. DeAngelis,Edward A. Neuwelt,Brian P. O'Neill,Eckhard Thiel,Tamara Shenkier,Fransesc Graus,Martin J. van den Bent,John F. Seymour,Philip Poortmans,James O. Armitage,Franco Cavalli +19 more
TL;DR: An international group of experts meeting to review current standards of reporting and to formulate a consensus opinion regarding minimum baseline evaluation and common standards for assessing response to therapy hope that these guidelines will improve communication among investigators and comparability among clinical trials in a way that will allow to develop better therapies for patients.
Journal ArticleDOI
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
Georg Lenz,Martin Dreyling,Eva Hoster,Bernhard Wörmann,Ulrich Dührsen,Bernd Metzner,Hartmut Eimermacher,Andreas Neubauer,Hannes Wandt,Hjalmar Steinhauer,Sonja Martin,Else Heidemann,Ali Aldaoud,Reza Parwaresch,Joerg Hasford,Michael Unterhalt,Wolfgang Hiddemann +16 more
TL;DR: The combined immunochemotherapy with R-CHOP resulted in a significantly higher response rate and a prolongation of the TTF as compared with chemotherapy alone, and may serve as a new baseline regimen for advanced stage MCL.
Journal ArticleDOI
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network
Martin Dreyling,Georg Lenz,Eva Hoster,Achiel Van Hoof,Christian Gisselbrecht,Rudolf Schmits,Bernd Metzner,Lorenz Truemper,Marcel Reiser,Hjalmar Steinhauer,Jean-Michel Boiron,Marc Boogaerts,Ali Aldaoud,Vittorio Silingardi,Hanneke C. Kluin-Nelemans,Joerg Hasford,Reza Parwaresch,Michael Unterhalt,Wolfgang Hiddemann +18 more
TL;DR: Early consolidation by myeloablative radiochemotherapy followed by ASCT is feasible and results in a significant prolongation of PFS in advanced-stage MCL, and longer follow-up is needed to determine the effect on OS.
Related Papers (5)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang,Simon Rule,Peter Martin,Andre Goy,Rebecca Auer,Brad S. Kahl,Brad S. Kahl,Wojciech Jurczak,Ranjana H. Advani,Jorge E. Romaguera,Michael E. Williams,Jacqueline C. Barrientos,Ewa Chmielowska,John Radford,Stephan Stilgenbauer,Martin Dreyling,Wiesław Wiktor Jędrzejczak,Peter Johnson,Stephen E. Spurgeon,Lei Li,Liang Zhang,Kate J. Newberry,Zhishuo Ou,Nancy Cheng,Bingliang Fang,Jesse McGreivy,Fong Clow,Joseph J. Buggy,Betty Y. Chang,Darrin M. Beaupre,Lori Kunkel,Kristie A. Blum +31 more
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Eva Hoster,Martin Dreyling,Wolfram Klapper,Christian Gisselbrecht,Achiel Van Hoof,Hanneke C. Kluin-Nelemans,Michael Pfreundschuh,Marcel Reiser,Bernd Metzner,H. Einsele,Norma Peter,Wolfram Jung,Bernhard Wörmann,Wolf-Dieter Ludwig,Ulrich Dührsen,Hartmut Eimermacher,Hannes Wandt,Joerg Hasford,Wolfgang Hiddemann,Michael Unterhalt +19 more
Treatment of Older Patients with Mantle-Cell Lymphoma
Hanneke C. Kluin-Nelemans,Eva Hoster,Olivier Hermine,Jan Walewski,Marek Trneny,Christian H. Geisler,Stephan Stilgenbauer,Catherine Thieblemont,Ursula Vehling-Kaiser,J.K. Doorduijn,Bertrand Coiffier,Roswitha Forstpointner,H. Tilly,Lothar Kanz,P. Feugier,Michal Szymczyk,Michael Hallek,Stephan Kremers,Gérard Lepeu,Laurence Sanhes,Josée M. Zijlstra,R. Bouabdallah,P. J. Lugtenburg,Margaret Macro,Michael Pfreundschuh,Vít Procházka,F. Di Raimondo,Vincent Ribrag,Michael Uppenkamp,M. Andre,Wolfram Klapper,Wolfgang Hiddemann,Michael Unterhalt,Martin Dreyling +33 more
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias J. Rummel,Norbert Niederle,Georg Maschmeyer,G.-Andre Banat,Ulrich von Grünhagen,Christoph Losem,Dorothea Kofahl-Krause,Gerhard Heil,Manfred Welslau,Christina Balser,Ulrich Kaiser,Eckhart Weidmann,Heinz Dürk,Harald Ballo,Martina Stauch,Fritz Roller,Juergen Barth,Dieter Hoelzer,Axel Hinke,Wolfram Brugger +19 more